SELECT Trial Summary: Semaglutide and Cardiovascular Risk

SELECT is arguably the trial that converted obesity pharmacotherapy from a weight discussion into an outcomes discussion. In 17,604 adults with overweight or obesity and established cardiovascular disease, but without diabetes, semaglutide reduced major adverse cardiovascular events by 20% compared with placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90). [1]

That matters because it answered a question the field had struggled to answer for years: not merely whether treatment changes body weight, but whether it changes hard events.

The trial design

SELECT enrolled adults aged 45 years or older with previous cardiovascular disease and BMI criteria for overweight or obesity, but without diabetes, and tested semaglutide 2.4 mg weekly against placebo on top of standard care. [1] This was not a vanity-endpoint study. It was built around myocardial infarction, stroke, and cardiovascular death.

What most articles miss

SELECT was not a general obesity trial. It was a secondary-prevention cardiovascular trial in a specific high-risk population without diabetes. [1] The result does not mean semaglutide is now a substitute for statins, antiplatelets, blood-pressure control, or smoking cessation. It is additive medicine, not replacement medicine.

The cardiovascular benefit also should not be reduced to the scale alone. Later analyses suggest the benefit was not simply a crude function of kilograms lost. [2]

The UK context

For UK readers, the policy context is changing. NICE published final draft guidance in March 2026 appraising semaglutide for reducing major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity, with expected publication in May 2026. [3] That is a concrete sign that SELECT is not merely an academic result. It is moving practice and reimbursement conversations.

What this means in practice

SELECT is useful because it sharpens the conversation with patients who have established cardiovascular disease and also carry the metabolic burden of overweight or obesity. It becomes much harder to dismiss treatment as merely cosmetic once hard outcome data exist. But the trial also forces discipline. If a patient is in the SELECT phenotype, obesity management belongs inside a cardiovascular risk framework, not in a detached consumer weight-loss lane.

When to involve your clinician

If you have previous myocardial infarction, stroke, or peripheral arterial disease and meet weight criteria, SELECT makes this a discussion worth having with a serious clinician rather than a casual online prescriber. [1,3]

Bottom line

SELECT changed the field because it showed that semaglutide could lower major cardiovascular events in people with overweight or obesity and established CVD without diabetes. That is not a beauty result. It is a medicine result. [1,3]